Volker Schweikhard, PhD, with his sponsor Steven M. Block, PhD, at Stanford University, Stanford, California, is investigating, at the single molecule level, how certain transcription factors assist an enzyme called RNA polymerase II in faithfully copying the genetic information stored in our DNA to messenger RNAthe blueprint for the proteins in our body. Aberrant gene expression lies at the heart of cancer, and thus, a detailed understanding of the activities of specific transcription factors may open up a potential route toward cancer therapy.
Lara C. Skwarek, PhD, with her sponsor David Bilder, PhD, at the University of California, Berkeley, California, is examining epithelial-to-mesenchymal transitions (EMTs), cellular changes that are required for normal development. EMTs are also crucial benchmarks in tumor progression towards metastasis. She will be performing a genetic screen for new molecules involved in EMTs. These studies will broaden our knowledge of the role of EMTs in cancer progression with the additional goal of identifying new targets for cancer therapeutics.
Ian Y. Wong, PhD, with his sponsors Mehmet Toner, PhD, and Daniel Irimia, MD, PhD, at Massachusetts General Hospital, Charlestown, Massachusetts, is developing a new experimental platform for characterizing how cancer cells migrate in response to biochemical signals and 3D structural architectures. This approach may yield novel insights into how malignant cancer cells invade, which would aid the development of anti-metastatic therapies.
Dong Yan, PhD [HHMI Fellow] with his sponsor Norbert Perrimon, PhD, at Harvard Medical School, Boston, Massachusetts, is aiming to generate profiles of phosphorylation for each kinase and phosphatase enzyme in the genome, and to relate these profiles to their in vivo functions during development. Given the large number of kinase mutations associated with various can
|Contact: Yung S. Lie, PhD|
Damon Runyon Cancer Research Foundation